ArticleArthritis research & therapy2012
Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group.
Article in Arthritis research & therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Association between Gout and Erectile Dysfunction: A Systematic Review and Meta-Analysis.PloS one · 2016Pooled it
- Non-steroidal anti-inflammatory drug (NSAID) use is not associated with erectile dysfunction risk: results from the Prostate Cancer Prevention Trial.BJU international · 2016Trial
- Immune-mediated skin diseases and erectile dysfunction: mechanisms and multidisciplinary management.Frontiers in immunology · 2026Review
- Does vascular involvement affect erectile dysfunction in patients with Behçet's disease?: a single-center cross-sectional study.Sao Paulo medical journal = Revista paulista de medicina · 2026Article
- Erectile dysfunction in dermatology and venereology: From aetiopathogenic mechanisms to practical considerations for dermato-venereologists.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Review
- Sexual Dysfunction Is Common in Reproductive-Age Women with Systemic Sclerosis.Life (Basel, Switzerland) · 2025Article
- Uncovering the link between inflammatory rheumatic diseases and male reproductive health: a perspective on male infertility and sexual dysfunction.Rheumatology international · 2024Review
- Exploring complex links: inflammatory rheumatic diseases and men's health.Rheumatology international · 2024Review
- Reproductive Issues and Pregnancy Implications in Systemic Sclerosis.Clinical reviews in allergy & immunology · 2023Review
- Prevalence of erectile dysfunction in Thai scleroderma patients and associated factors.PloS one · 2023Article
- Prevalence and clinical associations with primary hypogonadism in male systemic sclerosis.Journal of scleroderma and related disorders · 2022Article
- Prevalence of Sexual Dysfunction in People With Systemic Sclerosis and the Associated Risk Factors: A Systematic Review.Sexual medicine · 2021Review
- Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis.Archives of rheumatology · 2019Article
- Erectile dysfunction is a common problem in interstitial lung diseases.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2017Article
- Erectile Dysfunction in Systemic Sclerosis.Current rheumatology reports · 2016Review
- [Dermatological diseases and sexuality. How to proceed?].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2015Review
- Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis.ISRN rheumatology · 2013Review
Corrections and comments
- Commented on by
Authors and funding
25 authors at 19 institutions in 10 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionErectile dysfunction (ED) is common in men with systemic sclerosis (SSc) but the demographics, risk factors and treatment coverage for ED are not well known.
methodThis study was carried out prospectively in the multinational EULAR Scleroderma Trial and Research database by amending the electronic data-entry system with the International Index of Erectile Function-5 and items related to ED risk factors and treatment. Centres participating in this EULAR Scleroderma Trial and Research substudy were asked to recruit patients consecutively.
resultsOf the 130 men studied, only 23 (17.7%) had a normal International Index of Erectile Function-5 score. Thirty-eight per cent of all participants had severe ED (International Index of Erectile Function-5 score ≤ 7). Men with ED were significantly older than subjects without ED (54.8 years vs. 43.3 years, P < 0.001) and more frequently had simultaneous non-SSc-related risk factors such as alcohol consumption. In 82% of SSc patients, the onset of ED was after the manifestation of the first non-Raynaud's symptom (median delay 4.1 years). ED was associated with severe cutaneous, muscular or renal involvement of SSc, elevated pulmonary pressures and restrictive lung disease. ED was treated in only 27.8% of men. The most common treatment was sildenafil, whose efficacy is not established in ED of SSc patients.
conclusionsSevere ED is a common and early problem in men with SSc. Physicians should address modifiable risk factors actively. More research into the pathophysiology, longitudinal development, treatment and psychosocial impact of ED is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.